Clinical Trial

Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 30, 2025 (before its estimated June 3, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN0361 in Adult healthy subjects and Adult Hypertriglyceridemic Subjects.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-06-18; most recent amendment 2025-12-29.
Status change: Recruiting → Active, Not Recruiting 2025-12-29
Status change: Not Yet Recruiting → Recruiting 2025-05-21
Trial Details
NCT Number NCT06471543
Lead Sponsor Ikaria Bioscience Pty Ltd
Conditions Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Enrollment 108 participants
Start Date 2024-09-30
Primary Completion 2026-06-03 (estimated)
Study Completion 2026-08-26 (estimated)
Updated on ClinicalTrials.gov 2025-12-30